Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Vascular Disruptive Agents For The Treatment Of Cancer
Download Vascular Disruptive Agents For The Treatment Of Cancer full books in PDF, epub, and Kindle. Read online Vascular Disruptive Agents For The Treatment Of Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Vascular Disruptive Agents for the Treatment of Cancer by : Tim Meyer
Download or read book Vascular Disruptive Agents for the Treatment of Cancer written by Tim Meyer and published by Springer Science & Business Media. This book was released on 2010-09-02 with total page 258 pages. Available in PDF, EPUB and Kindle. Book excerpt: Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis – vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005).
Book Synopsis Vascular Disruptive Agents for the Treatment of Cancer by :
Download or read book Vascular Disruptive Agents for the Treatment of Cancer written by and published by . This book was released on 2011-07-11 with total page 268 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Vascular-Targeted Therapies in Oncology by : Dietmar W. Siemann
Download or read book Vascular-Targeted Therapies in Oncology written by Dietmar W. Siemann and published by . This book was released on 2006 with total page 384 pages. Available in PDF, EPUB and Kindle. Book excerpt: Vascular-Targeted Therapies in Oncology provides an interesting insight to the current status and future potential of vascular-disrupting approaches in cancer management. Emphasis is placed on target development, preclinical assessment, and the use of such targeted approaches in combination with conventional treatment regimens and the current clinical status of these therapies.
Book Synopsis Preclinical Evaluation of Cardiotoxicity Associated with Vascular Disrupting Agents Used for the Treatment of Cancer by : Asma K. I. Mohamed
Download or read book Preclinical Evaluation of Cardiotoxicity Associated with Vascular Disrupting Agents Used for the Treatment of Cancer written by Asma K. I. Mohamed and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Antiangiogenic Agents in Cancer Therapy by : Beverly A. Teicher
Download or read book Antiangiogenic Agents in Cancer Therapy written by Beverly A. Teicher and published by Springer Science & Business Media. This book was released on 1998-12-28 with total page 445 pages. Available in PDF, EPUB and Kindle. Book excerpt: Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy. Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished , where the experimental therapeutics of antiangiogenic agents is going, and the continuing evolution of their role in cancer treatment and novel drug development.
Book Synopsis Design and Synthesis of Combretastatin A-1 Analogs, Small Molecule Vascular Disrupting Agents, and Bioreductive Triggers as Potential Therapeutic Agents for the Treatment of Cancer by : Benson Lee Nguyen
Download or read book Design and Synthesis of Combretastatin A-1 Analogs, Small Molecule Vascular Disrupting Agents, and Bioreductive Triggers as Potential Therapeutic Agents for the Treatment of Cancer written by Benson Lee Nguyen and published by . This book was released on 2010 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer is the second leading cause of death in the United States with over 550,000 deaths in 2009 and a devastating 7.9 million deaths worldwide in 2007. Vascular disrupting agents (VDAs) represent a novel method developed for the treatment of cancer. VDAs, such as combretastatin A1 phosphate (CA1P, Oxi4503) and combretastatin A4 phosphate (CA4P, ZybrestatTM, fosbretabulin), after undergoing phosphate cleavage by non-specific phosphatase enzymes, selectively bind to the colchicine site on tubulin, disrupting tubulin polymerization. The integrity of the microtubules that form the cytoskeleton of the endothelial cells that line the tumorvasculature is altered, causing tumor vasculature occlusion and collapse, thus preventing nutrients and oxygen from reaching the tumor. This leads to severe tumor hypoxia, tumor perfusion regression and tumor necrosis. A series of anticancer agents were designed to incorporate a VDA or cytotoxic agent linked to a bioreductive drug to form a bioreductive prodrug conjugate. When the bioreductive portion of the molecular conjugate is reduced, the linkage between the VDA and the bioreductive drug is broken, releasing the VDA in its active form to act upon the tumor vasculature. The reduced bioreductive drug becomes a chemotherapeutic agent that can damage the tumor cells. CA1 is a potent inhibitor of tubulin polymerization and it has been shown that CA1 undergoes a second mechanism of action against tumors. CA1 incorporates an ortho diphenolic moiety that can be oxidized to form an ortho quinone that can damage DNA. To further elucidate the biological mechanism of action of CA1, a synthetic methodology was developed to incorporate a radioisotope at a metabolically stable position. In addition, a total synthesis was designed to prepare each of the combretastatin A1 monophosphates in regioisomeric pure form.
Book Synopsis Medicinal Chemistry of Anticancer Drugs by : Carmen Avendaño
Download or read book Medicinal Chemistry of Anticancer Drugs written by Carmen Avendaño and published by Elsevier. This book was released on 2015-06-11 with total page 767 pages. Available in PDF, EPUB and Kindle. Book excerpt: Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design. - Presents information in a clear and concise way using a large number of figures - Historical background provides insights on how the process of drug discovery in the anticancer field has evolved - Extensive references to primary literature
Book Synopsis Synthesis of Novel Natural Product Hybrids as New Vascular Disrupting Agents for Cancer Chemotherapy by : Cecil C. Sigamoney
Download or read book Synthesis of Novel Natural Product Hybrids as New Vascular Disrupting Agents for Cancer Chemotherapy written by Cecil C. Sigamoney and published by . This book was released on 2011 with total page 224 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Southern Seminary Singers written by and published by . This book was released on 1955 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Antitumor and Vascular Disrupting Effects of Ombrabulin in Hepatocellular Carcinoma by : Tsz-Ching Chan
Download or read book Antitumor and Vascular Disrupting Effects of Ombrabulin in Hepatocellular Carcinoma written by Tsz-Ching Chan and published by Open Dissertation Press. This book was released on 2017-01-26 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: This dissertation, "Antitumor and Vascular Disrupting Effects of Ombrabulin in Hepatocellular Carcinoma" by Tsz-ching, Chan, 陳子楨, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Hepatocellular Carcinoma (HCC) the fifth most common cancer and the third leading cause of death among cancer worldwide. Curative treatments such as liver resection and liver transplantation are generally used in treating early-stage HCC patients. However, only 10% to 30% of HCC patients are eligible for the surgery, which is due to the asymptomatic characteristic of HCC, most HCC patients are diagnosed at late stage. Palliative treatment such as TAE, TACE and Sorafenib provide them options to maintain their quality of life and extend their survival. Nevertheless, current treatments provides limited benefits to them as efficacy remains unsatisfactory. Therefore, there is a great need to develop new palliative treatments and explore new agents for the treatment of HCC. The aim of this study is to investigate the efficacy of a new therapeutic agent, Ombrabulin, in the treatment of HCC. Angiogenesis in HCC has been well-studied for many years as many studies proved that angiogeneisis plays an important role in the progression and development of HCC. Angiogenesis can also affect the prognosis and efficacy of treatments in HCC. As a result, antiangiogenesis and vascular disrupting agents have become new target in the therapaies of HCC. Ombrabulin is a synthetic vascular disrupting agent, which can inhibit tubulin polymerization in endothelial cells, causing cytoskeleton disorganization in endothelial cells. Endothelial cells will then detach from the basement membrane and eventually lead to vascular shutdown. This study demonstrated for the first time that Ombrabulin could selectively inhibit human umbilical vein endothelial cell (HUVEC) growth in vitro; particularly the early-form of HUVEC, which represent immature endothelial cell in neovasculature. Furthermore, this study also demonstrated the antiangiogenic effect of Ombrabulin on endothelial cells. By F-actin staining, it was shown that Ombrabulin caused changes in HUVECs morphology, which supported that Ombrabulin could lead to distortion in cytoskeleton. In vivo study demonstrated the early effect and long term effect of Ombrabulin. For the first part of the in vivo study, Nude mice were treated with single-dose of Ombrabulin for one week. Hoechst 33342, anti-CD34 staining and PCNA staining were carried out to study the functional effect of Ombrabulin and the combination effect with Sorafenib in vivo. Mice treated with Ombrabulin resulted in decreased blood perfusion, microvessel density and tumor cell proliferation, and tumor necrosis was also observed. In the combination with Sorafenib, it did not show synergistic effect in both tumor cell proliferation and microvessel density. For the second part of the in vivo study, nod scid mice were treated with multiple doses of Ombrabulin for three weeks to study the long term effect of Ombrabulin. Mice treated with Ombrabulin resulted in significantly smaller tumor size, demonstrating its antitumor efficacy in HCC. Furthermore, combination treatment of Sorafenib and Ombrabulin in vivo could enhance the efficacy of the treatment of HCC. In conclusion, Ombrabulin has vascular disrupting and antitumor effects, which could efficiently suppress HCC tumor growth in vivo. These results suggest that Ombrabulin could be a promising vascular disrupting agent in treating HCC. Combination with sorafenib should be further explored in clinical studies to demonstrate t
Book Synopsis Targeted Therapies in Oncology, Second Edition by : Giuseppe Giaccone
Download or read book Targeted Therapies in Oncology, Second Edition written by Giuseppe Giaccone and published by CRC Press. This book was released on 2013-10-21 with total page 500 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.
Book Synopsis Antiangiogenic Cancer Therapy by : Darren W Davis
Download or read book Antiangiogenic Cancer Therapy written by Darren W Davis and published by CRC Press. This book was released on 2019-08-30 with total page 864 pages. Available in PDF, EPUB and Kindle. Book excerpt: Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment. Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers. This volume celebrates progress made in four decades, and more importantly, it provi
Book Synopsis Metronomic Chemotherapy by : Guido Bocci
Download or read book Metronomic Chemotherapy written by Guido Bocci and published by Springer. This book was released on 2014-09-04 with total page 302 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.
Book Synopsis Marine Compounds and Cancer by : Friedemann Honecker
Download or read book Marine Compounds and Cancer written by Friedemann Honecker and published by MDPI. This book was released on 2018-06-26 with total page 119 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a printed edition of the Special Issue "Marine Compounds and Cancer" that was published in Marine Drugs
Book Synopsis Design and Synthesis of Dihydronaphthalene Vascular Disrupting Agents and Indolequinone-based Bioreductives by : Abhishek Dogra
Download or read book Design and Synthesis of Dihydronaphthalene Vascular Disrupting Agents and Indolequinone-based Bioreductives written by Abhishek Dogra and published by . This book was released on 2006 with total page 109 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer remains a deadly affliction for millions across the United States, and the number of new cases is only expected to rise in the years to come. In the field of anticancer research, vascular disrupting agents (VDAs) that preferentially target the tumor vasculature show great promise. The naturally occurring combretastatins, especially combretastatin A-4 (CA4) and combretastatin A-1 (CA1), in suitable prodrug form, have proven to be highly effective VDAs. In this study, efforts were directed towards the synthesis of two combretastatin analogs bearing key features of CA4 on a dihydronaphthalene framework: Oxi 6196 and a beta-dihydronaphthalene analog. In addition to VDAs, another class of exciting anticancer drugs is bioreductive agents that are selectively targeted towards the hypoxic region of tumors. These compounds are chemically reduced selectively and intracellularly to form active cytotoxic compounds. This study also presents the design and synthesis of two analogs of indolequinone-based prodrugs, which can be triggered to release an attached VDA upon bioreductive activation from the 3- or the 2-position, as well as the attempted synthesis of a CA4-tirapazamine bioconjugate drug.
Author :United States. Public Health Service. Office of the Surgeon General Publisher : ISBN 13 : Total Pages :728 pages Book Rating :4.:/5 (318 download)
Book Synopsis How Tobacco Smoke Causes Disease by : United States. Public Health Service. Office of the Surgeon General
Download or read book How Tobacco Smoke Causes Disease written by United States. Public Health Service. Office of the Surgeon General and published by . This book was released on 2010 with total page 728 pages. Available in PDF, EPUB and Kindle. Book excerpt: This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.
Book Synopsis Oncoimmunology by : Laurence Zitvogel
Download or read book Oncoimmunology written by Laurence Zitvogel and published by Springer. This book was released on 2017-12-13 with total page 700 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.
